Biosimilar vs originator insulins: Systematic review and meta-analysisCitation formats

  • External authors:
  • Tomohide Yamada
  • Ryuichi Kamata
  • Kotomi Ishinohachi
  • Nobuhiro Shojima
  • Hisashi Nom
  • Toshimasa Yamauchi
  • Takashi Kadowaki

Standard

Biosimilar vs originator insulins: Systematic review and meta-analysis. / Yamada, Tomohide; Kamata, Ryuichi; Ishinohachi, Kotomi; Shojima, Nobuhiro; Ananiadou, Sophia; Nom, Hisashi; Yamauchi, Toshimasa; Kadowaki, Takashi.

In: Diabetes, Obesity and Metabolism, Vol. 20, No. 7, 01.07.2018, p. 1787-1792.

Research output: Contribution to journalArticle

Harvard

Yamada, T, Kamata, R, Ishinohachi, K, Shojima, N, Ananiadou, S, Nom, H, Yamauchi, T & Kadowaki, T 2018, 'Biosimilar vs originator insulins: Systematic review and meta-analysis', Diabetes, Obesity and Metabolism, vol. 20, no. 7, pp. 1787-1792. https://doi.org/10.1111/dom.13291

APA

Yamada, T., Kamata, R., Ishinohachi, K., Shojima, N., Ananiadou, S., Nom, H., ... Kadowaki, T. (2018). Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 20(7), 1787-1792. https://doi.org/10.1111/dom.13291

Vancouver

Yamada T, Kamata R, Ishinohachi K, Shojima N, Ananiadou S, Nom H et al. Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2018 Jul 1;20(7):1787-1792. https://doi.org/10.1111/dom.13291

Author

Yamada, Tomohide ; Kamata, Ryuichi ; Ishinohachi, Kotomi ; Shojima, Nobuhiro ; Ananiadou, Sophia ; Nom, Hisashi ; Yamauchi, Toshimasa ; Kadowaki, Takashi. / Biosimilar vs originator insulins: Systematic review and meta-analysis. In: Diabetes, Obesity and Metabolism. 2018 ; Vol. 20, No. 7. pp. 1787-1792.

Bibtex

@article{2e6ed8f6252f4578a70d283e4b448966,
title = "Biosimilar vs originator insulins: Systematic review and meta-analysis",
abstract = "Biosimilar insulins have expanded the treatment options for diabetes. We compared the clinical efficacy and safety of biosimilar insulins with those of originator insulins by conducting a meta‐analysis. A random‐effects meta‐analysis was performed on randomized controlled trials comparing biosimilar and originator insulins in adults with diabetes. Studies were obtained by searching electronic databases up to December 2017. Ten trials, in a total of 4935 patients, were assessed (2 trials each on LY2963016, MK‐1293, Mylan's insulin glargine and SAR342434, and 1 trial each on FFP‐112 and Basalog). The meta‐analysis found no differences between long‐acting biosimilar and originator insulins with regard to reduction in glycated haemoglobin at 24 weeks (0.04{\%}, 95{\%} confidence interval [CI] –0.01, 0.08; P for efficacy = .14, I2 = 0{\%}) or at 52 weeks (0.03{\%}, 95{\%} CI –0.04, 0.1), or reduction in fasting plasma glucose (0.08 mmol/L, 95{\%} CI 0.36, 0.53), hypoglycaemia (odds ratio 0.99, 95{\%} CI 0.96, 1.03), mortality, injection site reactions, insulin antibodies and allergic reactions. Analyses stratified by type of diabetes and prior insulin use yielded similar findings. Similarly, no significant differences were found between short‐acting biosimilar and originator insulins. In summary, our meta‐analysis showed no significant differences in clinical efficacy and safety, including immune reactions, between biosimilar and originator insulins. Biosimilar insulins can increase access to modern insulin therapy and reduce medical costs.",
author = "Tomohide Yamada and Ryuichi Kamata and Kotomi Ishinohachi and Nobuhiro Shojima and Sophia Ananiadou and Hisashi Nom and Toshimasa Yamauchi and Takashi Kadowaki",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/dom.13291",
language = "English",
volume = "20",
pages = "1787--1792",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "John Wiley & Sons Ltd",
number = "7",

}

RIS

TY - JOUR

T1 - Biosimilar vs originator insulins: Systematic review and meta-analysis

AU - Yamada, Tomohide

AU - Kamata, Ryuichi

AU - Ishinohachi, Kotomi

AU - Shojima, Nobuhiro

AU - Ananiadou, Sophia

AU - Nom, Hisashi

AU - Yamauchi, Toshimasa

AU - Kadowaki, Takashi

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Biosimilar insulins have expanded the treatment options for diabetes. We compared the clinical efficacy and safety of biosimilar insulins with those of originator insulins by conducting a meta‐analysis. A random‐effects meta‐analysis was performed on randomized controlled trials comparing biosimilar and originator insulins in adults with diabetes. Studies were obtained by searching electronic databases up to December 2017. Ten trials, in a total of 4935 patients, were assessed (2 trials each on LY2963016, MK‐1293, Mylan's insulin glargine and SAR342434, and 1 trial each on FFP‐112 and Basalog). The meta‐analysis found no differences between long‐acting biosimilar and originator insulins with regard to reduction in glycated haemoglobin at 24 weeks (0.04%, 95% confidence interval [CI] –0.01, 0.08; P for efficacy = .14, I2 = 0%) or at 52 weeks (0.03%, 95% CI –0.04, 0.1), or reduction in fasting plasma glucose (0.08 mmol/L, 95% CI 0.36, 0.53), hypoglycaemia (odds ratio 0.99, 95% CI 0.96, 1.03), mortality, injection site reactions, insulin antibodies and allergic reactions. Analyses stratified by type of diabetes and prior insulin use yielded similar findings. Similarly, no significant differences were found between short‐acting biosimilar and originator insulins. In summary, our meta‐analysis showed no significant differences in clinical efficacy and safety, including immune reactions, between biosimilar and originator insulins. Biosimilar insulins can increase access to modern insulin therapy and reduce medical costs.

AB - Biosimilar insulins have expanded the treatment options for diabetes. We compared the clinical efficacy and safety of biosimilar insulins with those of originator insulins by conducting a meta‐analysis. A random‐effects meta‐analysis was performed on randomized controlled trials comparing biosimilar and originator insulins in adults with diabetes. Studies were obtained by searching electronic databases up to December 2017. Ten trials, in a total of 4935 patients, were assessed (2 trials each on LY2963016, MK‐1293, Mylan's insulin glargine and SAR342434, and 1 trial each on FFP‐112 and Basalog). The meta‐analysis found no differences between long‐acting biosimilar and originator insulins with regard to reduction in glycated haemoglobin at 24 weeks (0.04%, 95% confidence interval [CI] –0.01, 0.08; P for efficacy = .14, I2 = 0%) or at 52 weeks (0.03%, 95% CI –0.04, 0.1), or reduction in fasting plasma glucose (0.08 mmol/L, 95% CI 0.36, 0.53), hypoglycaemia (odds ratio 0.99, 95% CI 0.96, 1.03), mortality, injection site reactions, insulin antibodies and allergic reactions. Analyses stratified by type of diabetes and prior insulin use yielded similar findings. Similarly, no significant differences were found between short‐acting biosimilar and originator insulins. In summary, our meta‐analysis showed no significant differences in clinical efficacy and safety, including immune reactions, between biosimilar and originator insulins. Biosimilar insulins can increase access to modern insulin therapy and reduce medical costs.

U2 - 10.1111/dom.13291

DO - 10.1111/dom.13291

M3 - Article

VL - 20

SP - 1787

EP - 1792

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 7

ER -